Published in J Immunol Methods on March 27, 2010
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis (2014) 1.80
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J (2012) 1.04
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol (2015) 0.91
Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure. AAPS J (2012) 0.90
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84
Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis (2015) 0.77
Pre-existing Antibody: Biotherapeutic Modality-Based Review. AAPS J (2016) 0.77
Statistical and bioanalytical considerations for establishing a depletion criterion for specificity testing during immunogenicity assessment of a biotherapeutic. AAPS J (2013) 0.75
Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays. J Immunol Res (2016) 0.75
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs (2017) 0.75
Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine (2017) 0.75
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol (2007) 1.68
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 1.60
Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol (2007) 1.52
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods (2007) 1.42
Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol (2011) 1.40
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods (2005) 1.23
Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol (2013) 1.16
Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods (2010) 1.04
Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem (2005) 0.99
Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol (2007) 0.99
Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods (2012) 0.97
The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J Pharm Biomed Anal (2008) 0.96
Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol (2007) 0.96
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. Clin Cancer Res (2013) 0.89
Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant (2005) 0.88
Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. J Pharm Biomed Anal (2011) 0.86
Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods (2005) 0.85
Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies. Clin Vaccine Immunol (2007) 0.85
Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol (2005) 0.84
Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol Dial Transplant (2011) 0.83
Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis (2010) 0.83
Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods (2013) 0.81
Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol (2010) 0.81
Comparing exponentially weighted moving average and run rules in process control of semiquantitative immunogenicity immunoassays. AAPS J (2009) 0.81
Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J Immunol Methods (2004) 0.80
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas. Am J Respir Cell Mol Biol (2014) 0.79
Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J (2012) 0.79
Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin (2003) 0.79
Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol Annu Rev (2004) 0.78
Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. J Immunol Methods (2012) 0.78
Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis (2014) 0.77
Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis (2013) 0.76
A step-wise approach for transfer of immunogenicity assays during clinical drug development. AAPS J (2009) 0.75
Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum. J Pharm Biomed Anal (2006) 0.75
A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. J Immunol Methods (2006) 0.75
A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. J Pharm Biomed Anal (2007) 0.75